A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Clinical trial NCT02564198 · COMPLETED

Trial details

NCT number: NCT02564198
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pediatric Solid Tumor Refractory Tumor Recurrent Tumor CNS Malignancies

Start date: 2015-12-11
Primary completion: 2019-07-16
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.